These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 38637457

  • 1. Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease.
    Lamichhane N, Melas N, Bergqvist V, SWIBREG, Ekholm NP, Olén O, Ludvigsson JF, Hjortswang H, Marsal J, Eriksson C, Halfvarson J.
    Dig Dis Sci; 2024 Jun; 69(6):2175-2183. PubMed ID: 38637457
    [Abstract] [Full Text] [Related]

  • 2. An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study.
    D'Amico F, Massimino L, Palmieri G, Dal Buono A, Gabbiadini R, Caron B, Moreira P, Silva I, Bosca-Watts M, Innocenti T, Dragoni G, Bezzio C, Zilli A, Furfaro F, Saibeni S, Chaparro M, García MJ, Michalopoulos G, Viazis N, Mantzaris GJ, Ellul P, Gisbert JP, Magro F, Peyrin-Biroulet L, Armuzzi A, Ungaro F, Danese S, Fiorino G, Allocca M.
    Eur J Clin Invest; 2024 Nov; 54(11):e14283. PubMed ID: 38979834
    [Abstract] [Full Text] [Related]

  • 3. Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom.
    Lim SH, Gros B, Sharma E, Lehmann A, Lindsay JO, Caulfield L, Gaya DR, Taylor J, Limdi J, Kwok J, Shuttleworth E, Dhar A, Burdge G, Selinger C, Cococcia S, Murray C, Balendran K, Raine T, George B, Walker G, Aldridge R, Irving P, Lees CW, Samaan M.
    Inflamm Bowel Dis; 2024 Aug 01; 30(8):1284-1294. PubMed ID: 37603730
    [Abstract] [Full Text] [Related]

  • 4. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
    Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A.
    J Gastroenterol Hepatol; 2019 Dec 01; 34(12):2090-2095. PubMed ID: 31169926
    [Abstract] [Full Text] [Related]

  • 5. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O, Juillerat P, Biedermann L, Michetti P, Hruz P, Pittet V, Rogler G, Zahnd-Straumann N, Seibold F.
    United European Gastroenterol J; 2021 Apr 01; 9(3):398-406. PubMed ID: 33203339
    [Abstract] [Full Text] [Related]

  • 6. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
    Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Ferrante M, Jordi Guardiola, Jahnsen J, Louis E, Lukáš M, Reinisch W, Roblin X, Smith PJ, Kwon T, Kim J, Yoon S, Kim DH, Atreya R.
    BMC Gastroenterol; 2024 Mar 27; 24(1):121. PubMed ID: 38539103
    [Abstract] [Full Text] [Related]

  • 7. Real-life experiences of switching from intravenous to subcutaneous vedolizumab maintenance therapy in patients with inflammatory bowel disease.
    Kolehmainen S, Rautakorpi J, Löyttyniemi E, Af Björkesten CG, Arkkila P, Salminen K, Sipponen T.
    Eur J Gastroenterol Hepatol; 2024 Oct 01; 36(10):1193-1201. PubMed ID: 38973514
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
    Smith PJ, Critchley L, Storey D, Gregg B, Stenson J, Kneebone A, Rimmer T, Burke S, Hussain S, Yi Teoh W, Vazeille S, Serna S, Steel A, Derbyshire E, Collins P, Dibb M, Flanagan P, Probert C, Verma AM, Subramanian S.
    J Crohns Colitis; 2022 Sep 08; 16(9):1436-1446. PubMed ID: 35390141
    [Abstract] [Full Text] [Related]

  • 9. Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses.
    Harno-Tasihin J, Siregar L, Paajanen M, Arkkila P, Punkkinen J.
    Scand J Gastroenterol; 2024 Mar 08; 59(3):280-287. PubMed ID: 38006219
    [Abstract] [Full Text] [Related]

  • 10. Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS].
    Ventress E, Young D, Rahmany S, Harris C, Bettey M, Smith T, Moyses H, Lech M, Gwiggner M, Felwick R, Cummings JRF.
    J Crohns Colitis; 2022 Jul 14; 16(6):911-921. PubMed ID: 34935945
    [Abstract] [Full Text] [Related]

  • 11. Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.
    Bergqvist V, Holmgren J, Klintman D, Marsal J.
    Aliment Pharmacol Ther; 2022 Jun 14; 55(11):1389-1401. PubMed ID: 35470449
    [Abstract] [Full Text] [Related]

  • 12. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    Plevris N, Chuah CS, Allen RM, Arnott ID, Brennan PN, Chaudhary S, Churchhouse AMD, Din S, Donoghue E, Gaya DR, Groome M, Jafferbhoy HM, Jenkinson PW, Lam WL, Lyons M, Macdonald JC, MacMaster M, Mowat C, Naismith GD, Potts LF, Saffouri E, Seenan JP, Sengupta A, Shasi P, Sutherland DI, Todd JA, Veryan J, Watson AJM, Watts DA, Jones GR, Lees CW.
    J Crohns Colitis; 2019 Sep 19; 13(9):1111-1120. PubMed ID: 30768123
    [Abstract] [Full Text] [Related]

  • 13. Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring.
    Wiken TH, Høivik ML, Buer L, Warren DJ, Bolstad N, Moum BA, Anisdahl K, Småstuen MC, Medhus AW.
    Scand J Gastroenterol; 2023 Sep 19; 58(8):863-873. PubMed ID: 36799155
    [Abstract] [Full Text] [Related]

  • 14. Subcutaneous versus intravenous infliximab therapy - a real-world study: toward higher drug concentrations.
    Ferreira AI, Lima Capela T, Arieira C, Xavier S, Cotter J.
    Eur J Gastroenterol Hepatol; 2024 Nov 01; 36(11):1314-1318. PubMed ID: 39166409
    [Abstract] [Full Text] [Related]

  • 15. Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
    Volkers A, Straatmijer T, Duijvestein M, Sales A, Levran A, van Schaik F, Maljaars J, Gecse K, Ponsioen C, Grootjans J, Hanzel J, Tack G, Jansen J, Hoentjen F, de Boer N, van der Marel S, Dijkstra G, Oldenburg B, Löwenberg M, van der Meulen A, D Haens G, IBD center Amsterdam and the Dutch Initiative on Crohn and Colitis.
    Aliment Pharmacol Ther; 2022 Sep 01; 56(6):1044-1054. PubMed ID: 35869807
    [Abstract] [Full Text] [Related]

  • 16. Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease.
    Pintar Š, Hanžel J, Drobne D, Koželj M, Kurent T, Smrekar N, Novak G.
    Medicina (Kaunas); 2024 Feb 09; 60(2):. PubMed ID: 38399583
    [Abstract] [Full Text] [Related]

  • 17. Real-world experience of vedolizumab use in Colombian patients with inflammatory bowel disease-EXVEDOCOL.
    Parra V, Cifuentes S, Avendaño S, Ponce de León E, Florez C, Reyes G, Puentes F, Ballesteros M, Nuñez E, Gómez F, Márquez JR.
    Gastroenterol Hepatol; 2024 Oct 09; 47(8):858-866. PubMed ID: 38311006
    [Abstract] [Full Text] [Related]

  • 18. Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice.
    Pauwels RWM, de Vries AC, van der Woude CJ.
    J Gastroenterol Hepatol; 2020 Nov 09; 35(11):1893-1901. PubMed ID: 32291796
    [Abstract] [Full Text] [Related]

  • 19. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
    Reinglas J, Gonczi L, Verdon C, Bessissow T, Afif W, Wild G, Seidman E, Bitton A, Lakatos PL.
    Dig Dis Sci; 2020 Jul 09; 65(7):2046-2053. PubMed ID: 31813132
    [Abstract] [Full Text] [Related]

  • 20. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC, Bressler B.
    Immunotherapy; 2014 Jul 09; 6(9):963-71. PubMed ID: 25341118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.